Merrimack Non Current Liabilities Total vs Short Term Debt Analysis

MACK Stock

USD 14.73 0.02 0.14%

Merrimack Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Merrimack Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Merrimack Pharmaceuticals is a good investment. Please check the relationship between Merrimack Pharmaceuticals Non Current Liabilities Total and its Short Term Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.

Non Current Liabilities Total vs Short Term Debt

Non Current Liabilities Total vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Merrimack Pharmaceuticals Non Current Liabilities Total account and Short Term Debt. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Merrimack Pharmaceuticals' Non Current Liabilities Total and Short Term Debt is 0.45. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Merrimack Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Merrimack Pharmaceuticals' Non Current Liabilities Total and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Merrimack Pharmaceuticals are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Non Current Liabilities Total i.e., Merrimack Pharmaceuticals' Non Current Liabilities Total and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.45

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Non Current Liabilities Total

Short Term Debt

Most indicators from Merrimack Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merrimack Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.Tax Provision is expected to rise to about 12.6 K this year, although the value of Selling General Administrative will most likely fall to 2,067.

	2023	2024 (projected)
Total Operating Expenses	2.2M	2.1M
Cost Of Revenue	400.5K	380.5K

Total Operating Expenses Cost Of Revenue

Merrimack Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Other Assets
Common Stock Shares Outstanding		-0.33	0.04	-0.57	-0.5	0.49	-0.2	0.65	0.13	-0.53	-0.39	-0.22	-0.45	0.14	-0.29	-0.79	-0.49	-0.31	0.79	-0.52	-0.2	-0.3	0.08	-0.78	-0.75	0.2
Total Assets	-0.33		0.66	0.67	0.76	-0.34	0.83	-0.02	0.34	-0.22	0.43	0.79	0.92	0.27	0.98	-0.05	0.64	0.68	0.01	0.71	0.83	1.0	0.54	-0.05	0.69	0.09
Short Long Term Debt Total	0.04	0.66		0.54	0.76	-0.5	0.93	0.37	0.84	-0.82	0.1	0.58	0.66	-0.11	0.57	-0.19	0.6	0.34	0.43	0.68	0.93	0.65	0.76	-0.19	0.32	0.42
Other Current Liab	-0.57	0.67	0.54		0.87	-0.61	0.74	-0.11	0.42	-0.11	-0.05	0.45	0.78	-0.06	0.61	0.43	0.67	0.31	-0.27	0.76	0.74	0.63	0.21	0.43	0.65	0.17
Total Current Liabilities	-0.5	0.76	0.76	0.87		-0.67	0.89	0.11	0.61	-0.35	0.21	0.56	0.86	-0.05	0.66	0.3	0.74	0.43	-0.09	0.84	0.89	0.72	0.47	0.3	0.64	0.27
Total Stockholder Equity	0.49	-0.34	-0.5	-0.61	-0.67		-0.6	0.22	-0.44	0.15	-0.1	-0.33	-0.57	0.38	-0.19	-0.26	-0.93	-0.45	0.47	-0.91	-0.6	-0.29	-0.32	-0.26	-0.68	-0.21
Property Plant And Equipment Net	-0.2	0.83	0.93	0.74	0.89	-0.6		0.22	0.69	-0.59	0.17	0.72	0.86	-0.02	0.75	-0.05	0.75	0.47	0.17	0.83	1.0	0.81	0.69	-0.05	0.56	0.32
Current Deferred Revenue	0.65	-0.02	0.37	-0.11	0.11	0.22	0.22		0.35	-0.63	-0.38	0.08	-0.09	0.06	0.02	-0.4	-0.26	-0.32	0.71	-0.18	0.22	0.0	0.41	-0.4	-0.57	0.14
Net Debt	0.13	0.34	0.84	0.42	0.61	-0.44	0.69	0.35		-0.86	0.06	0.06	0.39	-0.31	0.21	-0.25	0.42	0.26	0.49	0.49	0.69	0.32	0.38	-0.25	0.16	0.5
Retained Earnings	-0.53	-0.22	-0.82	-0.11	-0.35	0.15	-0.59	-0.63	-0.86		0.12	-0.16	-0.2	0.11	-0.14	0.51	-0.16	-0.02	-0.79	-0.22	-0.59	-0.22	-0.54	0.51	0.2	-0.53
Accounts Payable	-0.39	0.43	0.1	-0.05	0.21	-0.1	0.17	-0.38	0.06	0.12		0.17	0.39	0.17	0.38	-0.07	0.27	0.71	-0.15	0.27	0.17	0.43	0.03	-0.07	0.58	0.0
Cash	-0.22	0.79	0.58	0.45	0.56	-0.33	0.72	0.08	0.06	-0.16	0.17		0.73	0.27	0.79	0.07	0.57	0.34	-0.04	0.6	0.72	0.78	0.81	0.07	0.45	0.03
Non Current Assets Total	-0.45	0.92	0.66	0.78	0.86	-0.57	0.86	-0.09	0.39	-0.2	0.39	0.73		0.3	0.83	0.12	0.78	0.66	-0.14	0.84	0.86	0.89	0.44	0.12	0.74	0.34
Non Currrent Assets Other	0.14	0.27	-0.11	-0.06	-0.05	0.38	-0.02	0.06	-0.31	0.11	0.17	0.27	0.3		0.28	-0.11	-0.2	0.1	0.17	-0.17	-0.02	0.25	-0.08	-0.11	-0.14	0.46
Cash And Short Term Investments	-0.29	0.98	0.57	0.61	0.66	-0.19	0.75	0.02	0.21	-0.14	0.38	0.79	0.83	0.28		-0.05	0.51	0.6	0.03	0.58	0.75	0.99	0.53	-0.06	0.62	-0.07
Common Stock Total Equity	-0.79	-0.05	-0.19	0.43	0.3	-0.26	-0.05	-0.4	-0.25	0.51	-0.07	0.07	0.12	-0.11	-0.05		0.13	-0.25	-0.63	0.18	-0.05	-0.08	-0.12	1.0	0.26	-0.1
Non Current Liabilities Total	-0.49	0.64	0.6	0.67	0.74	-0.93	0.75	-0.26	0.42	-0.16	0.27	0.57	0.78	-0.2	0.51	0.13		0.67	-0.41	0.98	0.75	0.6	0.45	0.13	0.83	0.17
Other Current Assets	-0.31	0.68	0.34	0.31	0.43	-0.45	0.47	-0.32	0.26	-0.02	0.71	0.34	0.66	0.1	0.6	-0.25	0.67		-0.22	0.64	0.47	0.67	0.18	-0.25	0.78	0.04
Other Stockholder Equity	0.79	0.01	0.43	-0.27	-0.09	0.47	0.17	0.71	0.49	-0.79	-0.15	-0.04	-0.14	0.17	0.03	-0.63	-0.41	-0.22		-0.35	0.17	0.05	0.29	-0.63	-0.58	0.36
Total Liab	-0.52	0.71	0.68	0.76	0.84	-0.91	0.83	-0.18	0.49	-0.22	0.27	0.6	0.84	-0.17	0.58	0.18	0.98	0.64	-0.35		0.83	0.67	0.48	0.18	0.82	0.2
Property Plant And Equipment Gross	-0.2	0.83	0.93	0.74	0.89	-0.6	1.0	0.22	0.69	-0.59	0.17	0.72	0.86	-0.02	0.75	-0.05	0.75	0.47	0.17	0.83		0.81	0.69	-0.05	0.56	0.32
Total Current Assets	-0.3	1.0	0.65	0.63	0.72	-0.29	0.81	0.0	0.32	-0.22	0.43	0.78	0.89	0.25	0.99	-0.08	0.6	0.67	0.05	0.67	0.81		0.55	-0.08	0.67	0.04
Short Term Debt	0.08	0.54	0.76	0.21	0.47	-0.32	0.69	0.41	0.38	-0.54	0.03	0.81	0.44	-0.08	0.53	-0.12	0.45	0.18	0.29	0.48	0.69	0.55		-0.12	0.16	0.04
Common Stock	-0.78	-0.05	-0.19	0.43	0.3	-0.26	-0.05	-0.4	-0.25	0.51	-0.07	0.07	0.12	-0.11	-0.06	1.0	0.13	-0.25	-0.63	0.18	-0.05	-0.08	-0.12		0.26	-0.1
Other Liab	-0.75	0.69	0.32	0.65	0.64	-0.68	0.56	-0.57	0.16	0.2	0.58	0.45	0.74	-0.14	0.62	0.26	0.83	0.78	-0.58	0.82	0.56	0.67	0.16	0.26		-0.11
Other Assets	0.2	0.09	0.42	0.17	0.27	-0.21	0.32	0.14	0.5	-0.53	0.0	0.03	0.34	0.46	-0.07	-0.1	0.17	0.04	0.36	0.2	0.32	0.04	0.04	-0.1	-0.11

Click cells to compare fundamentals

Merrimack Pharmaceuticals Account Relationship Matchups

Merrimack Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	13.4M	13.4M	13.4M	13.5M	14.3M	10.9M
Total Assets	20.1M	16.8M	14.7M	19.8M	19.2M	18.2M
Other Current Liab	2.5M	647K	442K	401K	367K	348.7K
Total Current Liabilities	2.8M	770K	562K	589K	441K	419.0K
Total Stockholder Equity	17.3M	16.0M	14.2M	19.2M	18.7M	19.7M
Net Debt	(16.6M)	(14.0M)	(14.2M)	(19.4M)	(6.0M)	(5.7M)
Retained Earnings	(540.6M)	(543.6M)	(546.1M)	(547.6M)	(548.8M)	(576.3M)
Accounts Payable	271K	123K	120K	188K	74K	70.3K
Cash	16.6M	14.0M	14.2M	19.4M	6.0M	5.7M
Non Current Assets Total	1.4M	232K	66K	8K	4K	3.8K
Non Currrent Assets Other	1.4M	232K	66K	8K	4K	3.8K
Cash And Short Term Investments	16.6M	14.0M	14.2M	19.4M	18.9M	17.9M
Liabilities And Stockholders Equity	20.1M	16.8M	14.7M	19.8M	19.2M	18.2M
Non Current Liabilities Total	14.9M	271K	123K	120K	589K	0.0
Other Current Assets	2.1M	2.5M	480K	389K	309K	293.6K
Other Stockholder Equity	556.6M	558.3M	558.9M	565.5M	566.2M	507.8M
Total Liab	2.8M	770K	562K	589K	441K	419.0K
Total Current Assets	18.7M	16.5M	14.7M	19.8M	19.2M	18.2M
Other Assets	2.7M	1.4M	232K	66K	8K	0.0
Net Tangible Assets	17.3M	16.0M	14.2M	19.2M	22.1M	23.2M
Retained Earnings Total Equity	(523.3M)	(540.6M)	(543.6M)	(547.6M)	(492.9M)	(517.5M)
Capital Surpluse	580.8M	556.6M	558.3M	565.5M	650.4M	625.9M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merrimack Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merrimack Pharmaceuticals' short interest history, or implied volatility extrapolated from Merrimack Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merrimack Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merrimack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merrimack Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Merrimack Pharmaceuticals Stock:

How To Invest In Merrimack

Details

Is Merrimack Stock a good investment?

Details

What is Merrimack Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.

Note that the Merrimack Pharmaceuticals information on this page should be used as a complementary analysis to other Merrimack Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Merrimack Stock analysis

When running Merrimack Pharmaceuticals' price analysis, check to measure Merrimack Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merrimack Pharmaceuticals is operating at the current time. Most of Merrimack Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Merrimack Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merrimack Pharmaceuticals' price. Additionally, you may evaluate how the addition of Merrimack Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Fundamental Analysis View fundamental data based on most recent published financial statements

Is Merrimack Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merrimack Pharmaceuticals. If investors know Merrimack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merrimack Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.08)

Return On Assets

(0.07)

Return On Equity

(0.06)

The market value of Merrimack Pharmaceuticals is measured differently than its book value, which is the value of Merrimack that is recorded on the company's balance sheet. Investors also form their own opinion of Merrimack Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Merrimack Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merrimack Pharmaceuticals' market value can be influenced by many factors that don't directly affect Merrimack Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merrimack Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Merrimack Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merrimack Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merrimack Non Current Liabilities Total vs Short Term Debt Analysis

Non Current Liabilities Total vs Short Term Debt

Non Current Liabilities Total vs Short Term Debt Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Short Term Debt

Merrimack Pharmaceuticals fundamental ratios Correlations

Merrimack Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Merrimack Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Merrimack Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Liab	+ 0.98	Non Current Liabilities Total

Non Current Liabilities Total	- 0.93	Total Stockholder Equity
Total Liab	- 0.91	Total Stockholder Equity
Retained Earnings	- 0.86	Net Debt
Retained Earnings	- 0.82	Short Long Term Debt Total
Other Stockholder Equity	- 0.79	Retained Earnings
Common Stock Total Equity	- 0.79	Common Stock Shares Outstanding